Rhinomaris spray 0.1%, 15 ml
Expiration Date: 05/2027
Russian Pharmacy name:
Риномарис спрей 0,1%, 15 мл
Acute respiratory diseases with symptoms of rhinitis (rhinitis);
allergic rhinitis (hay fever);
sinusitis;
eustachitis;
otitis media (to reduce swelling of the nasopharyngeal mucosa);
preparation of the patient for diagnostic manipulations in the nasal passages.
RinomarisЃ nasal spray, dosed 0.1% Children over 6 years old and adults: 1 injection into each nostril 2-3 times / day. The drug should not be used more than 4 times / day.
The duration of the course is no more than 5-7 days.
Spray nasal 0.1% in the form of a clear, odorless solution.
1 ml
xylometazoline hydrochloride 1 mg
Excipients: water of the Adriatic Sea - 245.98 mg, potassium dihydrogen phosphate - 0.502 mg, purified water - up to 1 ml.
Arterial hypertension;
tachycardia;
severe atherosclerosis;
glaucoma;
atrophic rhinitis;
thyrotoxicosis;
surgical interventions on the meninges (in history);
children under 6 years of age (for nasal spray 0.1%);
children under 2 years of age (for nasal spray 0.05%);
hypersensitivity to the components of the drug.
The drug should be used with caution in diabetes mellitus, angina pectoris (IHD).
pharmachologic effect
The drug is for intranasal use.
Xylometazoline has an alpha-adrenomimetic effect: it causes narrowing of the blood vessels of the nasal mucosa and thus eliminates edema and hyperemia of the nasopharyngeal mucosa. Eases nasal breathing with rhinitis. In therapeutic concentrations, it does not irritate the mucous membrane, does not cause hyperemia.
The action occurs within a few minutes after application and lasts for 12 hours.
Sterilized sea water, which is part of the RinomarisЃ preparation, helps to maintain the normal physiological state of the nasal mucosa, dilute mucus and normalize its production in the goblet cells of the nasal mucosa.
Trace elements improve the function of the ciliated epithelium, which helps to reduce side local reactions, such as irritation and / or dryness of the nasopharyngeal mucosa.
Pharmacokinetics
When applied topically, it is practically not absorbed, plasma concentrations are so small that they cannot be determined by modern analytical methods.
Side effect
From the respiratory system: with frequent and / or prolonged use - irritation and / or dryness of the nasopharyngeal mucosa, burning, tingling, sneezing, hypersecretion, swelling of the nasal mucosa.
From the side of the cardiovascular system: palpitations, tachycardia, arrhythmias, increased blood pressure.
From the nervous system: headache, insomnia; with long-term use in high doses - depression.
Others: vomiting, visual impairment.
Application during pregnancy and lactation
During pregnancy and lactation, the drug should be used only after a careful assessment of the risk-benefit ratio for the mother and the fetus or infant. Exceeding the recommended doses is not allowed.
Application in children
RinomarisЃ 0.1% nasal spray is contraindicated in children under 6 years of age, 0.05% nasal spray is contraindicated in children under 2 years of age.
special instructions
Before use, you must clean the nasal passages.
RinomarisЃ should not be used for a long time, for example, for chronic rhinitis.
Influence on the ability to drive vehicles and mechanisms
Xylometazoline in doses higher than recommended may affect the ability to drive vehicles or equipment.
Overdose
Symptoms: increased side effects.
Treatment: carrying out symptomatic therapy.
Drug interactions
RinomarisЃ is incompatible with MAO inhibitors and tricyclic antidepressants.